Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility

Baloxavir marboxil has been used for influenza treatment since March 2018 in Japan. After baloxavir treatment, the most frequently detected substitution is Ile38Thr in polymerase acidic protein (PA/I38T), and this substitution reduces baloxavir susceptibility in influenza A viruses. To rapidly inves...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2021-04, Vol.188, p.105036-105036, Article 105036
Hauptverfasser: Osada, Hidekazu, Chon, Irina, Phyu, Wint Wint, Wagatsuma, Keita, Nagata, Nobuo, Kawashima, Takashi, Sato, Isamu, Saito, Tadashi, Kodo, Naoki, Masaki, Hironori, Asoh, Norichika, Tsuchihashi, Yoshiko, Shirahige, Yutaka, Ono, Yasuhiko, Shimada, Yasushi, Hamabata, Hirotsune, Saito, Kousuke, Saito, Reiko
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 105036
container_issue
container_start_page 105036
container_title Antiviral research
container_volume 188
creator Osada, Hidekazu
Chon, Irina
Phyu, Wint Wint
Wagatsuma, Keita
Nagata, Nobuo
Kawashima, Takashi
Sato, Isamu
Saito, Tadashi
Kodo, Naoki
Masaki, Hironori
Asoh, Norichika
Tsuchihashi, Yoshiko
Shirahige, Yutaka
Ono, Yasuhiko
Shimada, Yasushi
Hamabata, Hirotsune
Saito, Kousuke
Saito, Reiko
description Baloxavir marboxil has been used for influenza treatment since March 2018 in Japan. After baloxavir treatment, the most frequently detected substitution is Ile38Thr in polymerase acidic protein (PA/I38T), and this substitution reduces baloxavir susceptibility in influenza A viruses. To rapidly investigate the frequency of PA/I38T in influenza A (H1N1)pdm09 and A (H3N2) viruses in clinical samples, we established a rapid real-time system to detect single nucleotide polymorphisms in PA, using cycling probe real-time PCR. We designed two sets of probes that were labeled with either 6-carboxyfluorescein (FAM) or 6-carboxy-X-rhodamine (ROX) to identify PA/I38 (wild type strain) or PA/I38T, respectively. The established cycling probe real-time PCR system showed a dynamic linear range of 101 to 106 copies with high sensitivity in plasmid DNA controls. This real-time PCR system discriminated between PA/I38T and wild type viruses well. During the 2018/19 season, 377 influenza A-positive clinical samples were collected in Japan before antiviral treatment. Using our cycling probe real-time PCR system, we detected no (0/129, 0.0%) influenza A (H1N1)pdm09 viruses with PA/I38T substitutions and four A (H3N2) (4/229, 1.7%) with PA/I38T substitution prior to treatment. In addition, we found PA/I38T variant in siblings who did not received baloxavir treatment during an infection caused by A (H3N2) that afflicted the entire family. Although human-to-human transmission of PA/I38T variant may have occurred in a closed environment, the prevalence of this variant in influenza A viruses was still limited. Our cycling probe-PCR system is thus useful for antiviral surveillance of influenza A viruses possessing PA/I38T. •We established cycling probe Real-time PCR systems to detect influenza A viruses with PA/I38T.•Pre-treatment prevalence of the PA/I38T mutant virus was 0.0% (0/129) for A (H1N1)pdm09 and 1.7% (4/229) for A/H3N2.•A(H3N2) PA/I38T viruses may be transmitted among humans in closed environments.
doi_str_mv 10.1016/j.antiviral.2021.105036
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2489260270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354221000267</els_id><sourcerecordid>2489260270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-ae65c6abdbc2ffabc7953ad3f95dd847c2e841545c9f999f729e721ff3e41b323</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi0EokvhFcBHLtk6dhLHx9UCpVIlECpny3_GXa-cOMTOluW5-oB4taVXTiNbv2--mfkQ-lCTdU3q7mq_VmP2Bz-rsKaE1uW3Jax7gVZ1z2kliOheolUhu4q1Db1Ab1LaE0I6LvrX6IKxlvOe8BV6_AQHCHEaYMw4OmyOJvjxHk9z1IC1SmDxDCpU2Q-Av29_4AHyLtoY4v0RuzhjP7qwwPhH4Q0uAy0JEp5iKiWdGuVdkW2ublh_h9Xgx4iV8RanRafs85J9HLFKKRqvcvF68HlXDO1iykOrEH-r0rTgycCUvfbB5-Nb9MqpkODdU71EP798vtt-rW6_Xd9sN7eVaSjJlYKuNZ3SVhvqnNKGi5Ypy5xore0bbij0Td02rRFOCOE4FcBp7RyDptaMskv08dy3XOPXAinLwZc5QlAjxCVJ2vSCdoRyUlB-Rs1cdp_ByWn2g5qPsibyFJncy-fI5CkyeY6sKN8_mSx6APus-5dRATZnAMqqBw-zTMbDWA7kZzBZ2uj_a_IXoLmxYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489260270</pqid></control><display><type>article</type><title>Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Osada, Hidekazu ; Chon, Irina ; Phyu, Wint Wint ; Wagatsuma, Keita ; Nagata, Nobuo ; Kawashima, Takashi ; Sato, Isamu ; Saito, Tadashi ; Kodo, Naoki ; Masaki, Hironori ; Asoh, Norichika ; Tsuchihashi, Yoshiko ; Shirahige, Yutaka ; Ono, Yasuhiko ; Shimada, Yasushi ; Hamabata, Hirotsune ; Saito, Kousuke ; Saito, Reiko</creator><creatorcontrib>Osada, Hidekazu ; Chon, Irina ; Phyu, Wint Wint ; Wagatsuma, Keita ; Nagata, Nobuo ; Kawashima, Takashi ; Sato, Isamu ; Saito, Tadashi ; Kodo, Naoki ; Masaki, Hironori ; Asoh, Norichika ; Tsuchihashi, Yoshiko ; Shirahige, Yutaka ; Ono, Yasuhiko ; Shimada, Yasushi ; Hamabata, Hirotsune ; Saito, Kousuke ; Saito, Reiko</creatorcontrib><description>Baloxavir marboxil has been used for influenza treatment since March 2018 in Japan. After baloxavir treatment, the most frequently detected substitution is Ile38Thr in polymerase acidic protein (PA/I38T), and this substitution reduces baloxavir susceptibility in influenza A viruses. To rapidly investigate the frequency of PA/I38T in influenza A (H1N1)pdm09 and A (H3N2) viruses in clinical samples, we established a rapid real-time system to detect single nucleotide polymorphisms in PA, using cycling probe real-time PCR. We designed two sets of probes that were labeled with either 6-carboxyfluorescein (FAM) or 6-carboxy-X-rhodamine (ROX) to identify PA/I38 (wild type strain) or PA/I38T, respectively. The established cycling probe real-time PCR system showed a dynamic linear range of 101 to 106 copies with high sensitivity in plasmid DNA controls. This real-time PCR system discriminated between PA/I38T and wild type viruses well. During the 2018/19 season, 377 influenza A-positive clinical samples were collected in Japan before antiviral treatment. Using our cycling probe real-time PCR system, we detected no (0/129, 0.0%) influenza A (H1N1)pdm09 viruses with PA/I38T substitutions and four A (H3N2) (4/229, 1.7%) with PA/I38T substitution prior to treatment. In addition, we found PA/I38T variant in siblings who did not received baloxavir treatment during an infection caused by A (H3N2) that afflicted the entire family. Although human-to-human transmission of PA/I38T variant may have occurred in a closed environment, the prevalence of this variant in influenza A viruses was still limited. Our cycling probe-PCR system is thus useful for antiviral surveillance of influenza A viruses possessing PA/I38T. •We established cycling probe Real-time PCR systems to detect influenza A viruses with PA/I38T.•Pre-treatment prevalence of the PA/I38T mutant virus was 0.0% (0/129) for A (H1N1)pdm09 and 1.7% (4/229) for A/H3N2.•A(H3N2) PA/I38T viruses may be transmitted among humans in closed environments.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2021.105036</identifier><identifier>PMID: 33577807</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antiviral susceptibility ; Baloxavir marboxil ; Cycling probe real-time PCR ; Influenza virus ; PA/I38T substitution</subject><ispartof>Antiviral research, 2021-04, Vol.188, p.105036-105036, Article 105036</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-ae65c6abdbc2ffabc7953ad3f95dd847c2e841545c9f999f729e721ff3e41b323</citedby><cites>FETCH-LOGICAL-c420t-ae65c6abdbc2ffabc7953ad3f95dd847c2e841545c9f999f729e721ff3e41b323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2021.105036$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33577807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Osada, Hidekazu</creatorcontrib><creatorcontrib>Chon, Irina</creatorcontrib><creatorcontrib>Phyu, Wint Wint</creatorcontrib><creatorcontrib>Wagatsuma, Keita</creatorcontrib><creatorcontrib>Nagata, Nobuo</creatorcontrib><creatorcontrib>Kawashima, Takashi</creatorcontrib><creatorcontrib>Sato, Isamu</creatorcontrib><creatorcontrib>Saito, Tadashi</creatorcontrib><creatorcontrib>Kodo, Naoki</creatorcontrib><creatorcontrib>Masaki, Hironori</creatorcontrib><creatorcontrib>Asoh, Norichika</creatorcontrib><creatorcontrib>Tsuchihashi, Yoshiko</creatorcontrib><creatorcontrib>Shirahige, Yutaka</creatorcontrib><creatorcontrib>Ono, Yasuhiko</creatorcontrib><creatorcontrib>Shimada, Yasushi</creatorcontrib><creatorcontrib>Hamabata, Hirotsune</creatorcontrib><creatorcontrib>Saito, Kousuke</creatorcontrib><creatorcontrib>Saito, Reiko</creatorcontrib><title>Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>Baloxavir marboxil has been used for influenza treatment since March 2018 in Japan. After baloxavir treatment, the most frequently detected substitution is Ile38Thr in polymerase acidic protein (PA/I38T), and this substitution reduces baloxavir susceptibility in influenza A viruses. To rapidly investigate the frequency of PA/I38T in influenza A (H1N1)pdm09 and A (H3N2) viruses in clinical samples, we established a rapid real-time system to detect single nucleotide polymorphisms in PA, using cycling probe real-time PCR. We designed two sets of probes that were labeled with either 6-carboxyfluorescein (FAM) or 6-carboxy-X-rhodamine (ROX) to identify PA/I38 (wild type strain) or PA/I38T, respectively. The established cycling probe real-time PCR system showed a dynamic linear range of 101 to 106 copies with high sensitivity in plasmid DNA controls. This real-time PCR system discriminated between PA/I38T and wild type viruses well. During the 2018/19 season, 377 influenza A-positive clinical samples were collected in Japan before antiviral treatment. Using our cycling probe real-time PCR system, we detected no (0/129, 0.0%) influenza A (H1N1)pdm09 viruses with PA/I38T substitutions and four A (H3N2) (4/229, 1.7%) with PA/I38T substitution prior to treatment. In addition, we found PA/I38T variant in siblings who did not received baloxavir treatment during an infection caused by A (H3N2) that afflicted the entire family. Although human-to-human transmission of PA/I38T variant may have occurred in a closed environment, the prevalence of this variant in influenza A viruses was still limited. Our cycling probe-PCR system is thus useful for antiviral surveillance of influenza A viruses possessing PA/I38T. •We established cycling probe Real-time PCR systems to detect influenza A viruses with PA/I38T.•Pre-treatment prevalence of the PA/I38T mutant virus was 0.0% (0/129) for A (H1N1)pdm09 and 1.7% (4/229) for A/H3N2.•A(H3N2) PA/I38T viruses may be transmitted among humans in closed environments.</description><subject>Antiviral susceptibility</subject><subject>Baloxavir marboxil</subject><subject>Cycling probe real-time PCR</subject><subject>Influenza virus</subject><subject>PA/I38T substitution</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkc9u1DAQxi0EokvhFcBHLtk6dhLHx9UCpVIlECpny3_GXa-cOMTOluW5-oB4taVXTiNbv2--mfkQ-lCTdU3q7mq_VmP2Bz-rsKaE1uW3Jax7gVZ1z2kliOheolUhu4q1Db1Ab1LaE0I6LvrX6IKxlvOe8BV6_AQHCHEaYMw4OmyOJvjxHk9z1IC1SmDxDCpU2Q-Av29_4AHyLtoY4v0RuzhjP7qwwPhH4Q0uAy0JEp5iKiWdGuVdkW2ublh_h9Xgx4iV8RanRafs85J9HLFKKRqvcvF68HlXDO1iykOrEH-r0rTgycCUvfbB5-Nb9MqpkODdU71EP798vtt-rW6_Xd9sN7eVaSjJlYKuNZ3SVhvqnNKGi5Ypy5xore0bbij0Td02rRFOCOE4FcBp7RyDptaMskv08dy3XOPXAinLwZc5QlAjxCVJ2vSCdoRyUlB-Rs1cdp_ByWn2g5qPsibyFJncy-fI5CkyeY6sKN8_mSx6APus-5dRATZnAMqqBw-zTMbDWA7kZzBZ2uj_a_IXoLmxYQ</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Osada, Hidekazu</creator><creator>Chon, Irina</creator><creator>Phyu, Wint Wint</creator><creator>Wagatsuma, Keita</creator><creator>Nagata, Nobuo</creator><creator>Kawashima, Takashi</creator><creator>Sato, Isamu</creator><creator>Saito, Tadashi</creator><creator>Kodo, Naoki</creator><creator>Masaki, Hironori</creator><creator>Asoh, Norichika</creator><creator>Tsuchihashi, Yoshiko</creator><creator>Shirahige, Yutaka</creator><creator>Ono, Yasuhiko</creator><creator>Shimada, Yasushi</creator><creator>Hamabata, Hirotsune</creator><creator>Saito, Kousuke</creator><creator>Saito, Reiko</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202104</creationdate><title>Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility</title><author>Osada, Hidekazu ; Chon, Irina ; Phyu, Wint Wint ; Wagatsuma, Keita ; Nagata, Nobuo ; Kawashima, Takashi ; Sato, Isamu ; Saito, Tadashi ; Kodo, Naoki ; Masaki, Hironori ; Asoh, Norichika ; Tsuchihashi, Yoshiko ; Shirahige, Yutaka ; Ono, Yasuhiko ; Shimada, Yasushi ; Hamabata, Hirotsune ; Saito, Kousuke ; Saito, Reiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-ae65c6abdbc2ffabc7953ad3f95dd847c2e841545c9f999f729e721ff3e41b323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral susceptibility</topic><topic>Baloxavir marboxil</topic><topic>Cycling probe real-time PCR</topic><topic>Influenza virus</topic><topic>PA/I38T substitution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osada, Hidekazu</creatorcontrib><creatorcontrib>Chon, Irina</creatorcontrib><creatorcontrib>Phyu, Wint Wint</creatorcontrib><creatorcontrib>Wagatsuma, Keita</creatorcontrib><creatorcontrib>Nagata, Nobuo</creatorcontrib><creatorcontrib>Kawashima, Takashi</creatorcontrib><creatorcontrib>Sato, Isamu</creatorcontrib><creatorcontrib>Saito, Tadashi</creatorcontrib><creatorcontrib>Kodo, Naoki</creatorcontrib><creatorcontrib>Masaki, Hironori</creatorcontrib><creatorcontrib>Asoh, Norichika</creatorcontrib><creatorcontrib>Tsuchihashi, Yoshiko</creatorcontrib><creatorcontrib>Shirahige, Yutaka</creatorcontrib><creatorcontrib>Ono, Yasuhiko</creatorcontrib><creatorcontrib>Shimada, Yasushi</creatorcontrib><creatorcontrib>Hamabata, Hirotsune</creatorcontrib><creatorcontrib>Saito, Kousuke</creatorcontrib><creatorcontrib>Saito, Reiko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osada, Hidekazu</au><au>Chon, Irina</au><au>Phyu, Wint Wint</au><au>Wagatsuma, Keita</au><au>Nagata, Nobuo</au><au>Kawashima, Takashi</au><au>Sato, Isamu</au><au>Saito, Tadashi</au><au>Kodo, Naoki</au><au>Masaki, Hironori</au><au>Asoh, Norichika</au><au>Tsuchihashi, Yoshiko</au><au>Shirahige, Yutaka</au><au>Ono, Yasuhiko</au><au>Shimada, Yasushi</au><au>Hamabata, Hirotsune</au><au>Saito, Kousuke</au><au>Saito, Reiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2021-04</date><risdate>2021</risdate><volume>188</volume><spage>105036</spage><epage>105036</epage><pages>105036-105036</pages><artnum>105036</artnum><issn>0166-3542</issn><eissn>1872-9096</eissn><abstract>Baloxavir marboxil has been used for influenza treatment since March 2018 in Japan. After baloxavir treatment, the most frequently detected substitution is Ile38Thr in polymerase acidic protein (PA/I38T), and this substitution reduces baloxavir susceptibility in influenza A viruses. To rapidly investigate the frequency of PA/I38T in influenza A (H1N1)pdm09 and A (H3N2) viruses in clinical samples, we established a rapid real-time system to detect single nucleotide polymorphisms in PA, using cycling probe real-time PCR. We designed two sets of probes that were labeled with either 6-carboxyfluorescein (FAM) or 6-carboxy-X-rhodamine (ROX) to identify PA/I38 (wild type strain) or PA/I38T, respectively. The established cycling probe real-time PCR system showed a dynamic linear range of 101 to 106 copies with high sensitivity in plasmid DNA controls. This real-time PCR system discriminated between PA/I38T and wild type viruses well. During the 2018/19 season, 377 influenza A-positive clinical samples were collected in Japan before antiviral treatment. Using our cycling probe real-time PCR system, we detected no (0/129, 0.0%) influenza A (H1N1)pdm09 viruses with PA/I38T substitutions and four A (H3N2) (4/229, 1.7%) with PA/I38T substitution prior to treatment. In addition, we found PA/I38T variant in siblings who did not received baloxavir treatment during an infection caused by A (H3N2) that afflicted the entire family. Although human-to-human transmission of PA/I38T variant may have occurred in a closed environment, the prevalence of this variant in influenza A viruses was still limited. Our cycling probe-PCR system is thus useful for antiviral surveillance of influenza A viruses possessing PA/I38T. •We established cycling probe Real-time PCR systems to detect influenza A viruses with PA/I38T.•Pre-treatment prevalence of the PA/I38T mutant virus was 0.0% (0/129) for A (H1N1)pdm09 and 1.7% (4/229) for A/H3N2.•A(H3N2) PA/I38T viruses may be transmitted among humans in closed environments.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33577807</pmid><doi>10.1016/j.antiviral.2021.105036</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0166-3542
ispartof Antiviral research, 2021-04, Vol.188, p.105036-105036, Article 105036
issn 0166-3542
1872-9096
language eng
recordid cdi_proquest_miscellaneous_2489260270
source Elsevier ScienceDirect Journals Complete
subjects Antiviral susceptibility
Baloxavir marboxil
Cycling probe real-time PCR
Influenza virus
PA/I38T substitution
title Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A27%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20cycling%20probe%20based%20real-time%20PCR%20methodology%20for%20influenza%20A%20viruses%20possessing%20the%20PA/I38T%20amino%20acid%20substitution%20associated%20with%20reduced%20baloxavir%20susceptibility&rft.jtitle=Antiviral%20research&rft.au=Osada,%20Hidekazu&rft.date=2021-04&rft.volume=188&rft.spage=105036&rft.epage=105036&rft.pages=105036-105036&rft.artnum=105036&rft.issn=0166-3542&rft.eissn=1872-9096&rft_id=info:doi/10.1016/j.antiviral.2021.105036&rft_dat=%3Cproquest_cross%3E2489260270%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2489260270&rft_id=info:pmid/33577807&rft_els_id=S0166354221000267&rfr_iscdi=true